Vanessa Da Silva Silveira, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2014 | 1551 | 1.070 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 4 | 2010 | 56 | 0.600 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2024 | 214 | 0.520 |
Why?
|
Polymorphism, Genetic | 6 | 2012 | 4243 | 0.450 |
Why?
|
Cytochrome P-450 CYP2D6 | 3 | 2010 | 107 | 0.400 |
Why?
|
Epoxide Hydrolases | 3 | 2010 | 122 | 0.390 |
Why?
|
Cholangiocarcinoma | 2 | 2024 | 552 | 0.380 |
Why?
|
Leukemia, Lymphoid | 1 | 2020 | 310 | 0.350 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2020 | 99 | 0.340 |
Why?
|
Thymidylate Synthase | 3 | 2011 | 74 | 0.340 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2014 | 651 | 0.330 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 3 | 2011 | 106 | 0.330 |
Why?
|
Protein Kinase Inhibitors | 4 | 2024 | 5672 | 0.300 |
Why?
|
Bile Duct Neoplasms | 1 | 2024 | 605 | 0.300 |
Why?
|
Genes, ras | 1 | 2020 | 654 | 0.290 |
Why?
|
DNA Repair Enzymes | 1 | 2009 | 346 | 0.280 |
Why?
|
Adrenocortical Carcinoma | 1 | 2017 | 88 | 0.270 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2017 | 161 | 0.260 |
Why?
|
NF-kappa B | 3 | 2024 | 2490 | 0.240 |
Why?
|
Phthalazines | 1 | 2017 | 383 | 0.240 |
Why?
|
Dual-Specificity Phosphatases | 1 | 2024 | 71 | 0.230 |
Why?
|
Interleukin-3 | 2 | 2010 | 425 | 0.230 |
Why?
|
Cerebellar Neoplasms | 2 | 2019 | 586 | 0.220 |
Why?
|
Medulloblastoma | 2 | 2019 | 678 | 0.210 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2010 | 629 | 0.200 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2012 | 87 | 0.190 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2012 | 114 | 0.190 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2024 | 2223 | 0.190 |
Why?
|
Gene Expression Profiling | 6 | 2020 | 9420 | 0.190 |
Why?
|
RNA, Neoplasm | 3 | 2020 | 750 | 0.180 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1899 | 0.180 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2010 | 90 | 0.180 |
Why?
|
Brazil | 6 | 2012 | 1230 | 0.180 |
Why?
|
Apoptosis | 7 | 2024 | 9490 | 0.180 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2872 | 0.170 |
Why?
|
Tumor Suppressor Proteins | 1 | 2020 | 2805 | 0.170 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2917 | 0.170 |
Why?
|
Caspase 8 | 1 | 2010 | 190 | 0.170 |
Why?
|
Deoxycytidine | 1 | 2024 | 877 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2018 | 1136 | 0.170 |
Why?
|
Receptors, IgG | 1 | 2012 | 559 | 0.160 |
Why?
|
Cell Line, Tumor | 9 | 2024 | 16990 | 0.160 |
Why?
|
Xenobiotics | 1 | 2009 | 70 | 0.160 |
Why?
|
Paracoccidioides | 1 | 2008 | 3 | 0.160 |
Why?
|
Paracoccidioidomycosis | 1 | 2008 | 10 | 0.160 |
Why?
|
Femoral Neoplasms | 1 | 2008 | 84 | 0.150 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 242 | 0.150 |
Why?
|
Caspase 3 | 1 | 2010 | 731 | 0.150 |
Why?
|
Glioblastoma | 3 | 2020 | 3483 | 0.150 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3639 | 0.150 |
Why?
|
Hematopoietic Stem Cells | 1 | 2020 | 3397 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11742 | 0.150 |
Why?
|
Protein Array Analysis | 1 | 2019 | 400 | 0.140 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2019 | 457 | 0.140 |
Why?
|
Recombinant Fusion Proteins | 2 | 2010 | 3733 | 0.140 |
Why?
|
Benzamides | 2 | 2012 | 1371 | 0.130 |
Why?
|
Bone Diseases | 1 | 2008 | 418 | 0.120 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2020 | 3615 | 0.120 |
Why?
|
Cell Proliferation | 6 | 2024 | 10451 | 0.120 |
Why?
|
Cross Infection | 1 | 2023 | 1422 | 0.110 |
Why?
|
Pancreatic Neoplasms | 2 | 2024 | 5368 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8554 | 0.110 |
Why?
|
Genetics, Population | 1 | 2009 | 937 | 0.110 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 619 | 0.110 |
Why?
|
Cytidine | 1 | 2014 | 64 | 0.110 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2024 | 106 | 0.110 |
Why?
|
Promoter Regions, Genetic | 3 | 2018 | 5790 | 0.110 |
Why?
|
Bone Neoplasms | 2 | 2012 | 2529 | 0.110 |
Why?
|
DNA Modification Methylases | 1 | 2014 | 210 | 0.110 |
Why?
|
Antineoplastic Agents | 5 | 2020 | 13642 | 0.110 |
Why?
|
Mutation | 2 | 2024 | 30053 | 0.100 |
Why?
|
Cyclohexanones | 1 | 2012 | 30 | 0.100 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2024 | 296 | 0.100 |
Why?
|
Infant | 12 | 2019 | 36193 | 0.100 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2024 | 1728 | 0.100 |
Why?
|
Child, Preschool | 13 | 2020 | 42232 | 0.100 |
Why?
|
DNA-Binding Proteins | 3 | 2011 | 9610 | 0.100 |
Why?
|
Gene Frequency | 4 | 2012 | 3606 | 0.100 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2014 | 220 | 0.100 |
Why?
|
Child | 16 | 2023 | 80158 | 0.090 |
Why?
|
Drug Synergism | 3 | 2017 | 1757 | 0.090 |
Why?
|
RNA, Messenger | 3 | 2014 | 12794 | 0.090 |
Why?
|
Daunorubicin | 1 | 2020 | 157 | 0.090 |
Why?
|
Cerebellum | 1 | 2018 | 1501 | 0.090 |
Why?
|
Methotrexate | 2 | 2014 | 1719 | 0.090 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2011 | 350 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3779 | 0.080 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2011 | 767 | 0.080 |
Why?
|
Dacarbazine | 1 | 2011 | 559 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 4576 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2019 | 3713 | 0.080 |
Why?
|
DNA Repair | 3 | 2011 | 2046 | 0.070 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 617 | 0.070 |
Why?
|
Mitotane | 1 | 2017 | 20 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2811 | 0.070 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2010 | 705 | 0.070 |
Why?
|
DNA Methylation | 2 | 2019 | 4399 | 0.070 |
Why?
|
Shock, Septic | 1 | 2013 | 768 | 0.070 |
Why?
|
Humans | 31 | 2024 | 761596 | 0.070 |
Why?
|
Osteosarcoma | 1 | 2012 | 897 | 0.070 |
Why?
|
Genotype | 5 | 2012 | 12990 | 0.070 |
Why?
|
Histone Deacetylases | 1 | 2010 | 720 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2024 | 3605 | 0.060 |
Why?
|
Cisplatin | 2 | 2017 | 1652 | 0.060 |
Why?
|
Adolescent | 11 | 2020 | 88326 | 0.060 |
Why?
|
Gene Expression | 1 | 2008 | 7581 | 0.060 |
Why?
|
Recombinant Proteins | 2 | 2010 | 6534 | 0.060 |
Why?
|
ras Proteins | 1 | 2020 | 1054 | 0.060 |
Why?
|
Quinazolines | 1 | 2011 | 1371 | 0.060 |
Why?
|
Doxorubicin | 2 | 2017 | 2224 | 0.060 |
Why?
|
Prognosis | 5 | 2014 | 29629 | 0.060 |
Why?
|
Mitogen-Activated Protein Kinase Phosphatases | 1 | 2024 | 47 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2010 | 5870 | 0.060 |
Why?
|
MicroRNAs | 1 | 2020 | 3816 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2012 | 17904 | 0.060 |
Why?
|
Neutropenia | 1 | 2009 | 885 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2011 | 9032 | 0.060 |
Why?
|
Polymerase Chain Reaction | 3 | 2011 | 6075 | 0.060 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1486 | 0.050 |
Why?
|
Remission Induction | 1 | 2009 | 2397 | 0.050 |
Why?
|
Phosphorylation | 2 | 2019 | 8321 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2024 | 5305 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 2013 | 1964 | 0.050 |
Why?
|
Cell Hypoxia | 1 | 2014 | 657 | 0.050 |
Why?
|
Risk Factors | 4 | 2012 | 74213 | 0.050 |
Why?
|
Survival Rate | 2 | 2010 | 12723 | 0.050 |
Why?
|
Male | 16 | 2020 | 360846 | 0.050 |
Why?
|
DNA Primers | 2 | 2010 | 2820 | 0.050 |
Why?
|
DNA Damage | 1 | 2020 | 2449 | 0.040 |
Why?
|
Female | 16 | 2020 | 392705 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2023 | 1039 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 3492 | 0.040 |
Why?
|
Signal Transduction | 2 | 2024 | 23447 | 0.040 |
Why?
|
Cell Death | 1 | 2024 | 1679 | 0.040 |
Why?
|
Transcriptional Activation | 1 | 2014 | 1756 | 0.040 |
Why?
|
Histones | 1 | 2017 | 2580 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2012 | 6815 | 0.030 |
Why?
|
Femur Neck | 1 | 2008 | 314 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2010 | 1596 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2010 | 1869 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10766 | 0.030 |
Why?
|
Drug Antagonism | 1 | 2014 | 51 | 0.030 |
Why?
|
Base Sequence | 2 | 2010 | 12441 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2020 | 11530 | 0.030 |
Why?
|
Bacteria | 1 | 2023 | 2199 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2735 | 0.030 |
Why?
|
Mitotic Index | 1 | 2012 | 162 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2018 | 22176 | 0.020 |
Why?
|
Vincristine | 1 | 2014 | 1036 | 0.020 |
Why?
|
Alleles | 1 | 2012 | 6864 | 0.020 |
Why?
|
Environmental Pollutants | 1 | 2010 | 1277 | 0.020 |
Why?
|
Methylation | 1 | 2014 | 1084 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2018 | 6131 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3883 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 718 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2012 | 64685 | 0.020 |
Why?
|
Odds Ratio | 1 | 2011 | 9647 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2013 | 1175 | 0.020 |
Why?
|
Mice | 1 | 2024 | 81539 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2011 | 1171 | 0.020 |
Why?
|
Protein Transport | 1 | 2012 | 1967 | 0.020 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2013 | 1017 | 0.020 |
Why?
|
Animals | 2 | 2024 | 168475 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3810 | 0.020 |
Why?
|
Genetic Variation | 1 | 2010 | 6567 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2013 | 1723 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11076 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3801 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2012 | 4853 | 0.010 |
Why?
|
Blotting, Western | 1 | 2011 | 5035 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2713 | 0.010 |
Why?
|
Hemodynamics | 1 | 2013 | 4160 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2009 | 2510 | 0.010 |
Why?
|
Young Adult | 2 | 2019 | 59260 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4352 | 0.010 |
Why?
|
Adult | 3 | 2023 | 221210 | 0.010 |
Why?
|
Middle Aged | 3 | 2020 | 220921 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15936 | 0.010 |
Why?
|
Echocardiography | 1 | 2013 | 4989 | 0.010 |
Why?
|
Bone Marrow | 1 | 2010 | 2911 | 0.010 |
Why?
|
Cell Movement | 1 | 2012 | 5205 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2010 | 2986 | 0.010 |
Why?
|
Survival Analysis | 1 | 2010 | 10090 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8466 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39106 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14608 | 0.010 |
Why?
|
Aged | 2 | 2020 | 169310 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10774 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2012 | 80647 | 0.010 |
Why?
|
Brain | 1 | 2008 | 27121 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2008 | 36426 | 0.010 |
Why?
|
Time Factors | 1 | 2011 | 39969 | 0.010 |
Why?
|
Prospective Studies | 1 | 2013 | 54423 | 0.000 |
Why?
|
Infant, Newborn | 1 | 2009 | 26202 | 0.000 |
Why?
|